Cancer is among diseases associated with widespread deaths around the globe. Thus, there has been an increase in the demand for information relating to its treatment and management. The information is a result of intensive researches conducted by scientists in the biomedical field. The specific branch of medicine dealing with the prevention diagnosis and treatment of cancer is known as Oncology. In the fight against cancer, it has become apparent that understanding the influence of other fields in prevention and treatment is of the essence. One journal that has significantly been involved in disseminating information relating to Oncology is Oncotarget.
Oncotarget is a multidisciplinary traditional medical journal covering all aspects of oncology. The peer-reviewed journal moved from a weekly publication to being published two times in a week owing to increased demand. The demand was attributed to its impact and quality. Also, Oncotarget’s insightful, constructive, and multi peer-review has enabled authors to publish essential research papers. The journal accepts publications from different authors which are reviewed by a highly qualified and experienced who facilitate timely publishing of the papers. In essence, it has endeavored to explore different therapies, management approaches, and their impact on patients.
The online journal operates on a free-access basis. An issue may be printed if there is a particular demand. Oncotarget has been instrumental in the increased spread of significant scientific information, in particular, in the medical field. It has provided an ample platform to foster the application of basic and clinical science in the search for preventive and curative measures to deal with cancer. The journal introduced other sections covering Cell Biology, Neuroscience, Endocrinology, and Pharmacology among others. The idea has further enhanced Oncotarget’s role through linking of different biomedical fields. The integration of this knowledge is an essential step towards the fight against cancer.
Cancer is a serious disease that ends lives much too soon all around the world. With such a terrible disease, it’s no surprise that measures are being taken to help treat it more efficiently. Many of us, especially Eric Lefkofsky, wonder how we can better diagnose cancer and find the best treatments available. According to this recent article regarding the health field and cancer itself, Eric Lefkofsky believes that critical data is missing from today’s medical research systems.
Eric Lefkofsky founder and CEO of Tempus, which is a startup that aims to provide more successful accuracy in treating cancer by supplying data for both genomics and therapeutic data. This would allow doctors to fine-tune cancer treatments and provide better overall care for their patients. With Tempus, there is a free flow of information between researchers, clinicians, and others.
After his wife was diagnosed with breast cancer, Lefkofsky felt personally inclined to start and develop Tempus. The central idea behind Tempus is to build a technology layer above existing electronic medical records and pathology systems to aggregate the data and receive an edited version back with patterns of treatments and results, showing which have been proven to successful.
In addition to Tempus, Eric Lefkofsky is known for many other notable works. He is the co-founder of Groupon, which is a global e-commerce marketplace used by many around the world. In 2006, he opened up the Lefkofsky Family Foundation, which is a private charitable foundation.
He opened this foundation up with his wife, Liz, in order to enhance the lives in the communities it serves. With Tempus just being a small glimpse of his work in the healthcare industry, Lefkofsky also serves as a Trustee of Lurie Children’s Hospital of Chicago. He also has a passion for the arts, being a Trustee at the Art Institute of Chicago and Chairman of the Board of Trustee’s of Chicago’s Steppenwolf Theatre Company.
for more info: chicagoinno.streetwise.co/2016/07/22/eric-lefkofskys-next-move-curing-cancer-at-tempus/